Association between plasma ADAMTS-7 levels and ventricular remodeling in patients with acute myocardial infarction

Wenjing Wu†, Yifeng Zhou†, Yiyang Li‡, Jiahui Li, Yuannan Ke, Yong Wang and Jingang Zheng

Abstract

Background: The metalloproteinase family of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) degrades extracellular matrix. However, the relevance of the ADAMTS family to cardiovascular diseases remains largely unknown. The study aimed to examine plasma ADAMTS-7 levels in patients with acute myocardial infarction (AMI) and the relationship between plasma ADAMTS-7 levels and heart function.

Methods: This was a prospective study performed in 84 patients with ST-elevation myocardial infarction (STEMI), 70 patients with non-STEMI (NSTEMI), and 38 controls. Enzyme-linked immunosorbent assay (ELISA) was used to measure plasma ADAMTS-7 levels. Cardiac structure and function were assessed using two-dimensional transthoracic echocardiography. Patients were stratified according to left ventricular ejection fraction (LVEF) ≤35% or >35%.

Results: Plasma ADAMTS-7 levels were higher in patients with LVEF ≤35% compared with those with LVEF >35% (6.73 ± 2.47 vs. 3.22 ± 2.05 ng/ml, P < 0.05). Plasma ADAMTS-7 levels were positively correlated with brain natriuretic peptide (BNP), left ventricular mass index (LVMI), left ventricular end-diastolic diameter (LVEDD), and left ventricular end-systolic diameter (LVESD) and negatively correlated with the 6-min walk test (P < 0.05). According to the receiver operating characteristic (ROC) curve, using a cutoff value of plasma ADAMTS-7 of 5.69 ng/ml was associated with a specificity of 61.0% and a sensitivity of 87.6% for the diagnosis of heart failure after AMI. Logistic regression analysis indicated that the association between ADAMTS-7 and heart failure after AMI was independent from traditional cardiovascular risk factors and other biomarkers (odds ratio = 1.236, 95% confidence interval: 1.023 to 1.378, P = 0.021).

Conclusions: Elevated ADAMTS-7 level may be involved in ventricular remodeling after AMI.

Keywords: Ventricular remodeling, Acute myocardial infarction, ADAMTS-7

Background

An increasing number of patients are suffering from heart failure after acute myocardial infarction (AMI), which is associated with high morbidity and mortality [1,2]. Ventricular remodeling plays an essential role in the development of heart failure, and the extracellular matrix (ECM) plays a major role in the maintenance of ventricular shape, size, and function [3]. After AMI, very early degradation of ECM causes progressive dilation and thinning in the infarction zone, contributing to infarct expansion and leading to severe consequences including left ventricular (LV) rupture, dilation, and dysfunction [4]. In addition, subsequent ECM disruption in the non-infarction zone leads to progressive global LV dilation over weeks [4].

ECM degradation requires the activation of extracellular proteases, which in turn facilitates ventricular remodeling [5]. Matrix metalloproteinases (MMP) play an important role in matrix degradation and ventricular remodeling [6,7]. MMP activation and consequent fibrillar collagen breakdown are responsible for adverse ventricular remodeling [8]. However, broad-spectrum MMP inhibitors led to severe side effects in clinical trials, indicating that more comprehensive knowledge about proteinases is needed [9].

* Correspondence: victorzhang@sina.com
†Equal contributors
1Department of Cardiology, China-Japan Friendship Hospital, 2 Yinghua Dongjie, Beijing 100029, China

Full list of author information is available at the end of the article

© 2015 Wu et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Members of the recently identified metalloproteinase family of a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) also degrade ECM. However, the relevance of the ADAMTS family to cardiovascular disease remains largely unknown [10]. ADAMTS-7 degrades cartilage oligomeric matrix proteins (COMP) found in the heart [11] and has been involved in inflammatory arthritis and bone growth [10,12]. Recently, Wang et al. [13] reported that ADAMTS-7 was a novel proteolytic culprit in vascular remodeling by mediating vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries [14], as well as in neointimal thickening after cardiac injury [15]. Du et al. [16] reported that upregulation of ADAMTS-7 by miR-29 repression mediated vascular smooth muscle calcification. ADAMTS-7 is involved in the proliferative response to vascular injury in a way that is similar to the progressive phase of atherosclerosis [17].

Therefore, we hypothesized that ADAMTS-7 participates in ventricular remodeling mediated at least in part, by ADAMTS-7-dependent ECM degradation. In this pilot study, we selected patients with AMI (both ST-elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI)) to detect plasma ADAMTS-7 levels and to explore the association between heart function and plasma ADAMTS-7.

**Methods**

**Patients**

Patients with AMI hospitalized between December 2012 and December 2013 at the cardiology department of the China-Japan Friendship Hospital were recruited, including 84 patients with STEMI and 70 patients with NSTEMI. Thirty-eight controls were also recruited from patients who underwent angiography and who subsequently showed no evidence of AMI. The diagnostic criteria for STEMI and NSTEMI were based on the 2013 ACCF/AHA guidelines for the management of STEMI [18], and the 2011 ESC guidelines for the management of acute coronary syndrome without ST-segment elevation [19].

For patients with STEMI or NSTEMI, inclusion criteria were as follows: 1) positive for troponin I; 2) history of chest pain lasting ≥20 min, no response to nitroglycerine or ECG changes (STEMI: ST-segment elevation measured at J-point in two continuous leads or with new onset of left bundle branch block; NSTEMI: ST-segment shifts and T-wave changes); 3) patient presented at the hospital within 24 h of symptoms onset; 4) patient consented to the study and blood was sampled for ADAMTS-7 measurement before any intervention; and 5) signed the consent form. For controls, inclusion criteria were as follows: 1) complaints of ischemic pains; 2) angiography showed vascular stenosis <50%; 3) patient consented to the study, and blood was sampled for ADAMTS-7 measurement before any intervention; and 4) signed the consent form. For all subjects, exclusion criteria were as follows: 1) severe hepatic or renal insufficiency; 2) rheumatologic disorders; 3) malignancy; or 4) active infection.

The study protocol was approved by the research ethics committee of the China-Japan Friendship Hospital and all patients provided a written informed consent.

**Data collection**

Gender, age, body mass index (BMI), medical history, and results of laboratory examinations were collected from the hospital computer system.

**Sample collection**

Six-milliliter samples of whole blood were collected into EDTA anticoagulant tubes and were stored at 4°C. Samples were centrifuged for 15 min at 1,000 × g at 4°C within 30 min of collection. Samples were stored at −80°C until analysis.

**Plasma ADAMTS-7 levels and biochemical assays**

Plasma ADAMTS-7 levels were measured using an enzyme-linked immunosorbent assay (ELISA) for human ADAMTS-7 (Human ADAMTS-7 ELISA Kit; MyBioSource Inc., San Diego, CA, USA). Optical density was measured at 450 nm. The lowest detectable limit of ADAMTS-7 concentration was 1.529 ng/mL, according to the manufacturer's instructions, and the coefficient of variation was <10%. Brain natriuretic peptide (BNP), serum lipids, high-sensitivity C-reactive protein (hs-CRP), fasting blood glucose, and serum creatinine were measured using standard clinical methods at the China-Japan Friendship Hospital using a Hitachi 7600 series automatic analyzer (Hitachi, Tokyo, Japan).

**Echocardiography**

Cardiac structure and function were assessed using two-dimensional transthoracic echocardiography performed and interpreted by cardiologists specialized in echocardiography and who were blind to the patient's clinical status. Echocardiography was performed using a Vivid E9 Echopac system with a high-definition M5S probe (GE Healthcare, Waukesha, WI, USA). Gain settings and pulse repetition frequency were adjusted to optimize color saturation and to avoid aliasing. LV ejection fraction (LVEF) was calculated using the bpline Simpson method. LV end diastolic/systolic diameter (LVEDD/LVESD) and interventricular septum thickness (IVST) were measured and recorded [20]. The LV mass (LVM) was derived using the following formula: LVM (g) = 0.8 × (1.04 × (IVST + LVEDD + LVPWT)³ – LVEDD³) + 0.6 [21],
where LVPWT is the abbreviation for LV posterior wall thickness. LVM was subsequently adjusted for body surface area (BSA) to obtain the LVM index (LVMI) value: LVMI (g/m²) = LVM/BSA.

Patients with STEMI or NSTEMI were divided into two groups according to a LVEF ≤35% or >35%.

Six-min walk test

The 6-min walk test was conducted in an enclosed 30-m-long corridor. The patients were instructed to walk from end to end, covering as much ground as they could during the 6 min test. The supervisor sat in a chair at one end of the course and delivered a predetermined set of encouraging phrases such as ‘You are doing well’ or ‘Keep up the good work.’ The total distance was recorded.

Statistical analysis

SPSS 19.0 (IBM, Armonk, NY, USA) and Prism 5.0 (GraphPad Software Inc., San Diego, CA, USA) were used for data analysis. Descriptive data are presented as means ± standard deviation (SD) for normally distributed variables or as medians (interquartile range) for non-normally distributed variables and as frequencies for categorical variables. Comparisons were performed using independent t-tests (normally distributed), Mann–Whitney U-tests (non-normally distributed), or chi-squared tests (categorical data). Receiver operating characteristic (ROC) curve was used to determine specificity and sensitivity for predicting heart failure after AMI. Linear associations were assessed using the Kendall’s tau-b analysis. Binary logistic regression was used to identify the predictive impacts of plasma ADAMTS-7 on heart failure. The odd ratios (OR) and the corresponding 95% confidence intervals (95% CI) were calculated. Two-sided P values of <0.05 were considered significant.

Results

Patient characteristics

Age and frequency of hypertension, diabetes, and male gender were higher in patients with AMI compared with

| Characteristics                  | LVEF ≤35% (n = 42)       | LVEF >35% (n = 112)       | Controls (n = 38)       | P value |
|---------------------------------|--------------------------|---------------------------|-------------------------|---------|
| Age, years                      | 66.5 ± 12.4              | 68.7 ± 10.4               | 56.6 ± 11.5             | <0.05   |
| Gender, male/female             | 28/14 (66.7/33.3%)       | 71/41 (63.4/36.0%)        | 21/17 (53.6%/44.7%)     | <0.05   |
| BMI (kg/m²)                     | 24.4 ± 3.0               | 24.7 ± 3.8                | 26.1 ± 4.1              | 0.23    |
| History of smoking, n (%)      | 12 (28.6)                | 30 (26.5)                 | 11 (28.9)               | 0.42    |
| Serum creatinine >140 μmol/L, n (%) | 13 (30.95)² | 6 (5.36)²                | 0 (0.00)                | <0.05   |
| History of hypertension, n (%) | 28 (66.7)                | 73 (65.2)                 | 16 (42.1)               | <0.05   |
| History of diabetes, n (%)     | 19 (45.2)                | 54 (48.2)                 | 9 (23.7)                | <0.05   |
| Glucose (mmol/L)                | 8.17 ± 3.86              | 8.42 ± 3.56               | 5.64 ± 1.21             | 0.23    |
| Total cholesterol (mmol/L)      | 4.64 ± 0.85              | 4.36 ± 1.17               | 4.66 ± 0.89             | 0.90    |
| Triglycerides (mmol/L)          | 1.59 ± 1.21              | 1.38 ± 0.72               | 1.88 ± 1.34             | 0.08    |
| HDL-cholesterol (mmol/L)        | 1.07 ± 0.33              | 1.12 ± 0.29               | 1.06 ± 0.32             | 0.06    |
| LDL-cholesterol (mmol/L)        | 2.83 ± 0.84              | 2.72 ± 0.94               | 2.76 ± 0.64             | 0.97    |
| hsCRP (mg/L)                    | 12.32 ± 53.46            | 11.68 ± 38.48             | 4.89 ± 9.30             | <0.05   |
| Type of AMI, n (%)              |                          |                           |                         | <0.05   |
| STEMI                           | 33 (78.6)                | 51 (45.5)                 |                         |         |
| NSTEMI                          | 9 (21.4)                 | 61 (54.5)                 |                         |         |
| BNP                             | 1,670.71 ± 1,074.44⁴     | 433.72 ± 285.67⁴          | 60.69 ± 36.98           | <0.05   |
| LVEF                            | 28.43 ± 4.79⁴            | 47.31 ± 7.69⁴             | 57.42 ± 6.28            | <0.05   |
| LVMI                            | 90.51 ± 14.39⁴           | 70.43 ± 12.04⁴            | 82.67 ± 20.05           | <0.05   |
| LVEDD                           | 61.95 ± 4.80⁴            | 49.45 ± 4.72⁴             | 50.23 ± 5.98            | <0.05   |
| LVESD                           | 38.05 ± 5.73³            | 31.37 ± 4.08³             | 30.37 ± 4.15            | <0.05   |
| Six-min walk test               | 171.07 ± 70.32³          | 465.13 ± 189.00³          | 4.89 ± 9.30             | <0.05   |
| Plasma ADAMTS-7 levels          | 6.73 ± 2.47⁹             | 3.22 ± 2.05⁹              | 1.63 ± 1.58             | <0.05   |

²Mean P < 0.05 compared between the LVEF ≤35 group and LVEF >35% group; ³mean comparison between the three groups. ADAMTS, a disintegrin and metalloprotease with thrombospondin motifs; AMI, acute myocardial infarction; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter.
controls (*P* < 0.05). The proportion of patients with serum creatinine >140 μmol/l was significantly higher in patients with AMI. There were no differences in BMI, blood glucose, and blood lipids between groups (Table 1). Levels of high-sensitivity C-reactive protein (hsCRP) were elevated in patients with AMI compared with controls (*P* < 0.05).

### Plasma ADAMTS-7 in patients with AMI and LVEF ≤35% or LVEF >35%

Patients with AMI were divided according to LVEF ≤35% or >35%. Plasma levels of ADAMTS-7 were higher in patients with LVEF ≤35% compared with those with LVEF >35% (6.73 ± 2.47 vs. 3.22 ± 2.05 ng/ml, *P* < 0.05).

### Association between ADAMTS-7 levels and heart failure

The median ADAMTS-7 level among the 154 patients (84 STEMI patients and 70 NSTEMI patients) was 4.48 ng/ml (range: 0.34 to 14.26 ng/ml). Kendall’s tau-b analysis showed that plasma ADAMTS-7 levels were positively correlated with BNP (*r* = 0.732, *P* = 0.005), LVMI (*r* = 0.714, *P* = 0.02), LVEDD (*r* = 0.693, *P* = 0.04) and LVESD (*r* = 0.647, *P* = 0.03) and negatively correlated with the 6-min walk test (*r* = −0.653, *P* = 0.02) and LVEF (*r* = −0.624, *P* = 0.04) (Table 2).

According to the ROC curve, a cutoff value of plasma ADAMTS-7 of 5.68 ng/ml resulted in a specificity of 61.0% and a sensitivity of 87.6% for the diagnosis of heart failure after AMI (Figure 1).

To control for potential confounders, a multivariate analysis was performed. Age, gender, BMI, hypertension, hyperlipidemia, diabetes, blood glucose, total cholesterol, triglycerides, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, and hsCRP were set as independent variables, and heart failure was set as the dependent variable. Results indicated that elevated plasma ADAMTS-7 levels were independently associated with heart failure after AMI (OR = 1.236, 95% CI: 1.023 to 1.378, *P* = 0.021) as well as age (OR = 1.158, 95% CI: 1.013 to 1.438, *P* = 0.035) and hsCRP (OR = 1.285, 95% CI: 1.002 to 1.411, *P* = 0.016) (Table 3).

### Discussion

The aim of the present study was to examine plasma ADAMTS-7 levels in patients with AMI and the relationship between plasma ADAMTS-7 levels and heart function. Results showed that plasma ADAMTS-7 levels were higher in patients with LVEF ≤35% compared with those who had a LVEF >35%. Plasma ADAMTS-7 levels were positively correlated with BNP, LVMI, LVEDD, and LVESD and negatively correlated with the 6-min walk test, which is consistent with the role of MMP in the

| Variables                | Correlation coefficient (r) | P value |
|--------------------------|-----------------------------|---------|
| BNP                      | 0.732                       | 0.005   |
| LVMI                     | 0.714                       | 0.016   |
| LVEDD                    | 0.693                       | 0.038   |
| LVESD                    | 0.647                       | 0.026   |
| Six-min walk test        | −0.653                      | 0.024   |
| LVEF                     | −0.624                      | 0.041   |

95% CI, 95% confidence interval; ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; AMI, acute myocardial infarction; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; LVMI, left ventricular mass index; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter.

| Variables                | Exp (B)   | 95% CI for Exp (B) |
|--------------------------|-----------|--------------------|
| Age                      | 1.158     | 1.013 to 1.438     |
| Gender                   | 1.213     | 0.872 to 1.635     |
| BMI                      | 1.233     | 0.721 to 1.259     |
| Hypertension history     | 1.000     | 0.963 to 1.101     |
| Hyperlipidemia history   | 0.983     | 0.925 to 1.028     |
| Diabetes history         | 0.797     | 0.740 to 1.029     |
| hsCRP                    | 1.285     | 1.002 to 1.411     |
| Plasma ADAMTS-7          | 1.242     | 1.015 to 1.378     |
progression of ventricular remodeling [22]. According to the ROC curve, using a cut-off value of plasma ADAMTS-7 of 5.69 ng/ml was associated with a specificity of 61.0% and a sensitivity of 87.6% for the diagnosis of heart failure after AMI. Logistic regression analysis indicated that the association between ADAMTS-7 and heart failure after AMI was independent of traditional cardiovascular risk factors and other biomarkers.

The early induction of the enzymatic activity of ECM-degrading proteases precedes ventricular remodeling. From the therapeutic standpoint, inhibition of such proteases would be beneficial for the treatment of patients with heart failure. Given the disappointing side effects of broad-spectrum MMP inhibitors, more comprehensive knowledge about proteinases is needed [9]. Thus, unraveling the role of individual proteases in cardiovascular disease is of particular importance. To the best of our knowledge, the present study is the first to show an association between plasma ADAMTS-7 levels and LV function after AMI. Indeed, low LVEF after AMI is indicative of more extensive cardiac damage and is associated with a bad prognosis [23]. However, the exact implication of ADAMTS-7 in ventricular remodeling still needs to be exactly determined.

Unlike other metalloproteinases, ADAMTS demonstrates a narrow substrate specificity due to the various exosites located in the C-terminal regions of the enzymes, which influence protein recognition and matrix location [24], suggesting that ADAMTS could potentially be safe pharmaceutical targets [13]. ADAMTS-7 expression was detected as a 5-kb transcript in adult human samples, with the heart, pancreas, kidney, skeletal muscle, and liver having the highest levels of expression [13]. Previous studies demonstrated that ADAMTS-7 facilitates vascular muscle cell migration and intimal thickening after vascular injury and plays an important role in atherosclerosis and restenosis by degrading COMP [13-16]. Huang et al. [25] reported the presence of COMP in cardiomyocytes, where it plays an essential role during the initiation and progression of dilated cardiomyopathy. Therefore, it may be hypothesized that ADAMTS-7 affects the ventricular remodeling process by degrading COMP in patients with AMI. However, it is possible that ADAMTS-7 degrades other substrates. Nevertheless, a study showed an association between the ADAMTS-7 locus and angiographic coronary artery disease [15]. Further studies are necessary to assess the mechanisms of ADAMTS-7 in ventricular remodeling and heart diseases. Other members of the ADAMTS family also warrant investigation in AMI [26].

The present study is not without limitations. This was a single-center study with a relatively small sample size. For now, the cutoff value is purely suggestive since there is no established reference available from large clinical trials. Finally, the present study was not designed to provide any mechanistic insights into the roles of ADAMTS-7 in patients with heart failure after AMI. Larger multi-center trials are necessary to determine adequately the role of ADAMTS-7 in heart failure after AMI.

Conclusions
In conclusion, elevated ADAMTS-7 levels may be involved in ventricular remodeling after AMI. High ADAMTS-7 levels were independently associated with poor prognosis in patients with AMI.

Abbreviations
95% CI: 95% confidence intervals; AMI: acute myocardial infarction; BMI: body mass index; hs-CRP: high-sensitivity C-reactive protein; IVST: interventricular septum thickness; LVEDD: left ventricular end diastolic diameter; LVEF: left ventricular ejection fraction; LVMI: left ventricular mass index; MMP: matrix metalloproteinase; NSTEMI: non-ST-elevated myocardial infarction; OR: odds ratio; ROC: receiver operating characteristic; STEMI: ST-elevated myocardial infarction.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
WJW, YFZ, and JGZ have made substantial contributions to the conception and design of this study; WJW, YFZ, YYL, JHL, YNK, YW, and JGZ have made substantial contributions to the acquisition of data or analysis and interpretation of data; WJW, YFZ, and JGZ have been involved in drafting the manuscript or revising it critically for important intellectual content. All authors read and have given final approval of the version to be published.

Authors’ information
Wenjing Wu, Yifeng Zhou, Yiyang Li, Jiahui Li, Yuannan Ke, Yong Wang, and Jingang Zheng are doctors of medicine.

Acknowledgements
This work was supported by grants from the National Natural Science Fund (3077065; 81170287), the China-Japan Friendship Hospital Youth Science and Technology Excellence Project (2014-QNYC-B-13), and the China-Japan Friendship Hospital research topic within the hospital (2013-QN-26).

Author details
1Department of Cardiology, China-Japan Friendship Hospital, 2 Yinghua Dongjie, Beijing 100029, China. 2Department of Gynaecology, The First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China.

Received: 18 November 2014 Accepted: 6 March 2015
Published online: 21 March 2015

References
1. Kenchaiah S, Pfeffer MA, St John Sutton M, Pappert T, Rouleau JL, Lamas GA, et al. Effect of antecedent systemic hypertension on subsequent left ventricular dilation after acute myocardial infarction (from the Survival and Ventricular Enlargement trial). Am J Cardiol. 2004;94:1-8.
2. Heidenreich PA, Trogdon JS, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-44.
3. Rathi S, Deedwania PC. The epidemiology and pathophysiology of heart failure. Med Clin North Am. 2012;96:881-90.
4. Janicki JS, Brower GL. The role of myocardial fibrillar collagen in ventricular remodeling and function. J Card Fail. 2002;8:531-9.
5. Chan W, Duffy SJ, White DA, Gao XM, Du XJ, Ellims AH, et al. Acute left ventricular remodeling following myocardial infarction: coupling of regional healing with remote extracellular matrix expansion. JACC Cardiovasc Imaging. 2012;5:884–93.

6. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res. 2001;89:201–10.

7. Fedak PW, Altamentova SM, Weisel RD, Nili N, Ohno N, Verma S, et al. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol. 2003;284:H626–34.

8. Gajana JS, Kloner RA. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev. 2011;16:13–21.

9. Hughes BG, Schulz R. Targeting MMP-2 to treat ischemic heart injury. Basic Res Cardiol. 2014;109:424.

10. Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J. 2005;386:15–27.

11. Riessen R, Fenchel M, Chen H, Axel DI, Karsch KR, Lawler J. Cartilage oligomeric matrix protein (thrombospondin-5) is expressed by human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:47–54.

12. Liu CJ, Kong W, Ialov K, Yu S, Xu K, Prazak L, et al. ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein. FASEB J. 2006;20:988–90.

13. Wang L, Wang X, Kong W. ADAMTS-7, a novel proteolytic culprit in vascular remodeling. Sheng Li Xue Bao. 2010;62:285–94.

14. Wang L, Zheng J, Bai X, Liu B, Liu CJ, Xu Q, et al. ADAMTS-7 mediates vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries. Circ Res. 2009;104:688–98.

15. Reilly MP, Li M, He J, Ferguson JF, Styanou IM, Mehta NN, et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet. 2011;377:883–92.

16. Yu Y, Gao C, Liu Z, Wang L, Liu B, He F, et al. Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by miR-29 repression mediates vascular smooth muscle calcification. Arterioscler Thromb Vasc Biol. 2012;32:2580–8.

17. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–95.

18. O’Gara PT, Kushner FG, Ascheim DD, Casey Jr DE, Chung MK, de Lemos JA, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;127:e362–425.

19. Lempereur M, Moonen M, Gach O, Lancellotti P. European Society for C. 2013 ESC guidelines for the management of acute coronary syndromes without ST segment elevation. Rev Med Liege. 2012;67:8–10.

20. Sah J, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–83.

21. Devereux RB, Casale PN, Kligfield P, Eisenberg RR, Miller D, Campo E, et al. Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy. Am J Cardiol. 1986;57:1388–93.

22. Fertin M, Lemesle G, Turkieh A, Beseme O, Chwastyniak M, Amouyel P, et al. Serum MMP-8: a novel indicator of left ventricular remodeling and cardiac outcome in patients after acute myocardial infarction. PloS One. 2013;8:e71280.

23. Klem I, Shah DJ, White RD, Pennell DJ, van Rossum AC, Regenfus M, et al. Prognostic value of routine cardiac magnetic resonance assessment of left ventricular ejection fraction and myocardial damage: an international, multicenter study. Circ Cardiovasc Imaging. 2011;4:610–9.

24. Tortorella MD, Malfait F, Barve RA, Shieh HS, Malfait AM. A review of the ADAMTS family, pharmaceutical targets of the future. Curr Pharm Des. 2009;15:2359–74.

25. Huang Y, Xia J, Zheng J, Geng B, Liu P, Yu F, et al. Deficiency of cartilage oligomeric matrix protein causes dilated cardiomyopathy. Basic Res Cardiol. 2013;108:374.

26. Lee CW, Hwang I, Park CS, Lee H, Park DW, Kang SJ, et al. Comparison of ADAMTS-1,4 and-5 expression in culprit plaques between acute myocardial infarction and stable angina. J Clin Pathol. 2011;64:399–404.